# A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

> **NCT00401843** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 307 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Siltuximab
- **DRUG:** Bortezomib
- **DRUG:** Placebo
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT00401843
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11-28
- **Primary completion:** 2011-08-16
- **Final completion:** 2019-09-24
- **Target enrollment:** 307 (ACTUAL)
- **Last updated:** 2019-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00401843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00401843, "A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00401843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*